Home-based infusion therapy for patients with Fabry disease. - Wikidata - awgldk - TriplyDB

Home-based infusion therapy for patients with Fabry disease.

Home-based infusion therapy for patients with Fabry disease.

http://www.wikidata.org/entity/Q37194457

about

Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy Fabry disease: a review of current management strategies.Safety of agalsidase alfa in patients with Fabry disease under 7 years.Fabry disease

P2860

Q33847189-C67802E8-A19F-4269-BD5F-BBD7C55BF37C Q37775790-91B7BD48-A21A-4FC6-9B12-336F944D3B8F Q37813149-7FFF2CF1-F9DC-4E38-8B22-2A5B8B272F9C Q56905945-21B6231F-4C13-489B-8F43-24B2BB1784BF

P2860

Home-based infusion therapy for patients with Fabry disease.

http://www.wikidata.org/entity/Q37194457

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Home-based infusion therapy for patients with Fabry disease.

@en

Home-based infusion therapy for patients with Fabry disease.

@nl

type

label

Home-based infusion therapy for patients with Fabry disease.

@en

Home-based infusion therapy for patients with Fabry disease.

@nl

prefLabel

Home-based infusion therapy for patients with Fabry disease.

@en

Home-based infusion therapy for patients with Fabry disease.

@nl

P1433

Q37194457-889299ED-48D0-4040-8CCA-A7BE4629243A

P1476

Q37194457-C0DFC13F-2AFD-4C9D-9D4C-1E9476EAB43B

P2093

Q37194457-17BB1BE0-65A7-4F1F-BDAD-759DFB63A04C

Q37194457-33BEECF3-4103-4489-BB77-00AB27406822

Q37194457-47B92A3E-9CF7-46E8-9FBE-A84C426593B1

Q37194457-8C18C048-488D-475A-A62C-75389AEEDB6F

Q37194457-B3763D12-99F4-4DEA-8CA4-C9D2058D3199

Q37194457-C4EA3ACB-F695-4F93-A6DD-AC2D3C9D4F44

Q37194457-EED2A355-2ED0-4A33-973F-913929EDDC52

P2860

Q37194457-1C29AB2E-738C-454A-ABF3-63AC5E05B684

Q37194457-22853EB5-35AD-471F-81CB-858583B30A5E

Q37194457-2B61C715-EFD6-45CA-8569-C04B06EFBFAB

Q37194457-2B86D0A4-0154-423A-A253-7A25869224E5

Q37194457-3DF86819-18CE-4056-BFDB-F0D6914ACDF6

Q37194457-3F837EE1-B85C-44D8-AF41-5690D429E5B8

Q37194457-52F3E0BE-5631-4F04-8098-FF02A759A4AA

Q37194457-751ECBCA-56ED-4822-925F-EF9664D22168

Q37194457-A1B16CFF-628B-48BA-8245-FF77D14DF7E4

Q37194457-CF7060A3-9006-4F08-B1E0-209ABDC4F40B

P304

Q37194457-E10A4455-936D-4F68-B7F5-922655703F4A

P31

Q37194457-E4B5C3A4-893C-4ED3-B27B-5B617DBAA35A

P356

Q37194457-4B938A64-395B-44E6-9D85-B4118C921F0B

P433

Q37194457-A818A7EE-EDD1-4961-BB48-729ED4890997

P478

Q37194457-3D614060-682C-4498-9CBD-D1EBA9A16612

P577

Q37194457-D4DF1EF0-2BF6-4006-AC52-FFBB4875F966

P698

Q37194457-7083EEF2-4354-4145-9B24-B5325954C02E

P356

BJON.2008.17.10.29481

P1433

British Journal of Nursing

P1476

Home-based infusion therapy for patients with Fabry disease.

@en

P2093

A Cousins

http://www.w3.org/2001/XMLSchema#string

A Raas-Rothschild

http://www.w3.org/2001/XMLSchema#string

D Rorman

http://www.w3.org/2001/XMLSchema#string

L Thompson

http://www.w3.org/2001/XMLSchema#string

M Banikazemi

http://www.w3.org/2001/XMLSchema#string

P Lee

http://www.w3.org/2001/XMLSchema#string

S Waldek

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies

Prevalence of lysosomal storage disorders.

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.

Lysosomal storage disorders: the need for better pediatric recognition and comprehensive care.

Fabry disease: guidelines for the evaluation and management of multi-organ system involvement.

Treatment of lysosomal storage disorders : progress with enzyme replacement therapy.

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta.

Home treatment for Fabry disease: practice guidelines based on 3 years experience in The Netherlands.

P304

653-657

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.12968/BJON.2008.17.10.29481

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18563007

http://www.w3.org/2001/XMLSchema#string